Basiliximab
- Generic Name
- Basiliximab
- Brand Names
- Simulect
- Drug Type
- Biotech
- CAS Number
- 179045-86-4
- Unique Ingredient Identifier
- 9927MT646M
- Background
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.
- Indication
For prophylactic treatment of kidney transplant rejection
- Associated Conditions
- Rejection Acute Renal
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 893
- Registration Number
- NCT01011205
- Locations
- 🇫🇮
026, Helsinki, Finland
🇧🇾146, Minsk, Belarus
🇧🇪006, Gent, Belgium
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
- Conditions
- MyelofibrosisAnemia, AplasticHemoglobinuria, ParoxysmalAcute Myelogenous LeukemiaAcute Lymphocytic LeukemiaChronic Myelogenous LeukemiaChronic Lymphocytic LeukemiaMyelodysplasiaNon-Hodgkin's LymphomaHodgkin's Disease
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 17
- Registration Number
- NCT00975975
- Locations
- 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients
- Conditions
- Chronic Renal Failure
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT00965094
- Locations
- 🇮🇱
Novartis Investigative Site, Tel-Aviv, Israel
Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program
- Conditions
- Renal Transplantation
- Interventions
- Drug: Enteric Coated Mycophenolic Acid (MPA)Drug: Corticosteroids
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 207
- Registration Number
- NCT00956293
- Locations
- 🇩🇪
Novartis Investigative Site, München, Germany
Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
- Conditions
- Kidney Transplantation
- Interventions
- Drug: Corticosteroids
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 281
- Registration Number
- NCT00933231
- Locations
- 🇨🇦
Site CA133 Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦Site CA54 University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦Site CA27 London Health Sciences Centre, London, Ontario, Canada
Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Drexel University College of Medicine
- Target Recruit Count
- 5
- Registration Number
- NCT00928811
- Locations
- 🇺🇸
Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation
- Conditions
- Liver TransplantationChronic Renal Insufficiency
- Interventions
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2011-09-15
- Lead Sponsor
- Armin Goralczyk
- Target Recruit Count
- 29
- Registration Number
- NCT00890253
- Locations
- 🇩🇪
University Medical Center Goettingen, Goettingen, Germany
Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant
- Conditions
- Diabetes Mellitus, Type I
- Interventions
- Biological: Allogeneic Pancreatic Islet Cells
Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation
- Conditions
- Diabetes Mellitus, Type I
- Interventions
- Drug: Low Molecular Weight Sulfated Dextran (LMW-SD)Drug: Klexane® (Enoxaparinsodium)Drug: Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2021-09-28
- Target Recruit Count
- 24
- Registration Number
- NCT00789308
- Locations
- 🇳🇴
University Hospital Rikshospitalet, Oslo, Norway
🇸🇪Karolinska University Hospital, Stockholm, Sweden
🇸🇪Uppsala University Hospital, Uppsala, Sweden
A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00729768
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.